大规模生产含有IgY的药片,用于控制COVID-19的传播
Michelle Hawkins1, Brian Robley1, Farhang Alem2
1Camas Inc, Le Center, MN, 56057, USA.
Scientific reports
|November 11, 2025
概括
来自免疫的IgY抗体提供了一个可扩展和稳定的被动免疫策略. 这些IgY片有效中和所有主要的COVID-19变种,提供一个负担得起的全球健康解决方案.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 生物技术是生物技术.
背景情况:
- COVID-19疫苗已经减少了严重的疾病,但在全球范围内感染仍然存在,需要采取替代控制措施.
- 使用IgY (免疫球蛋白Y) 的被动免疫接种是一种公认的策略,在大流行期间获得了引力.
- 对抗SARS-CoV-2 IgY的可扩展生产对于广泛的可访问性至关重要.
研究的目的:
- 为了证明大规模生产抗COVID-19IgY的可行性.
- 在可食用药片中制定和测试IgY的稳定性和有效性.
- 评估对当前SARS-CoV-2变种的中和潜力.
主要方法:
- 超过7万只的免疫接种针对SARS-CoV-2 S1抗原.
- 从蛋黄中提取和净化抗S1IgY.
- 净化IgY的配方,制成食用药片,供人食用.
- 质量控制,稳定性测试和针对病毒变异的免疫反活性测试.
主要成果:
- 从超过7万只中成功大规模生产抗S1IgY.
- 抗体Y片维持了超过一年的活性和稳定性.
- IgY片显示出对所有主要的COVID-19变种的持续免疫活性和病毒中和.
结论:
- 将蛋黄粉制成可食药片是被动免疫的可行方法.
- 抗COVID-19IgY片提供了一种负担得起和有效的方法来阻止病毒感染和传播.
- 这一战略有可能在发达国家和发展中国家对当前的SARS-CoV-2变种进行广泛应用.
相关概念视频
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
293
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
293
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
186
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
186